Key Highlights

  • Shares are trading at $35.38 in pre-market activity, up 2.99% from Wednesday's close of $34.35.
  • Indivior declared a special Cash Dividend of $8.13 per share, contingent on completing its previously announced Merger with Supernus Pharmaceuticals.
  • The all-stock merger is expected to close around November 2, 2026, pending Shareholder approvals, creating a larger CNS-focused drugmaker.
  • The stock remains well below the average analyst price target range of roughly $43 to $49.

Special Dividend Sweetens Pending Supernus Merger

Indivior (NASDAQ:INDV) shares rose in pre-market trading Thursday after the company declared a special cash dividend of $8.13 per share, contingent on the completion of its previously announced all-stock merger with Supernus Pharmaceuticals (NASDAQ:SUPN). Indivior is a specialty pharmaceutical company headquartered in North Chesterfield, Virginia, focused on developing, manufacturing, and commercializing treatments for opioid use disorder, with a portfolio that includes Sublocade, Suboxone, Subutex, and the opioid overdose Reversal nasal spray Opvee.

The merger, expected to close around November 2, 2026 pending shareholder approvals, would combine Indivior with Supernus to create a larger company focused on central nervous system disorders, and the Special Dividend is designed to sweeten the deal terms for existing Indivior shareholders.

Move Follows a Softer Session Tied to a Supply Agreement Change

The gain follows a softer session on September 15, when shares dipped after Indivior announced it will terminate its longstanding supply agreement with Reckitt Benckiser for Suboxone and Subutex manufacturing, effective January 2027, as it transitions to a newly identified supplier the company says is not expected to be material to operations.

Investors Weigh Near-Term Transition Against the Merger's Strategic Case

Investors are weighing the near-term supply chain transition against the longer-term strategic rationale of the Supernus combination, with the stock continuing to trade well below the average analyst price target range of roughly $43 to $49, suggesting some skepticism remains about how quickly the deal's benefits will show up in the share price.

Outlook: Merger Timeline Becomes the Key Watch Point

Indivior shares are gaining as the special dividend adds a tangible near-term benefit to a merger story still working through shareholder approvals. Continued progress toward the November closing target, along with execution on the new Manufacturing supplier transition, will likely shape the stock's next move.